Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

20171,168 citationsJournal Articlebronze Open Access

Authors

Francisco M. Marty · Dana-Farber Cancer Institute

Per Ljungman · Karolinska Institutet

Roy F. Chemaly · The University of Texas MD Anderson Cancer Center

Johan Maertens · Karolinska University Hospital

Sanjeet Dadwal · City Of Hope National Medical Center

Rafael F. Duarte · Hospital Universitario Puerta de Hierro Majadahonda

Shariq Haider

Abstract

Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo. Adverse events with letermovir were mainly of low grade. (Funded by Merck; ClinicalTrials.gov number, NCT02137772 ; EudraCT number, 2013-003831-31 .).

Topics & Keywords

Cytomegalovirus and herpesvirus research Toxoplasma gondii Research Studies Herpesvirus Infections and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 25, pp. 2433-2444

DOI: 10.1056/nejmoa1706640

Field-Weighted Citation Impact: 63.05